Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?

SIMPLE SUMMARY: In oncology, a new era has emerged in the last ten years with the development of targeted and immune therapies. In hepatocellular carcinoma (HCC), several targeted agents (sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab) are approved and immunotherapy is now validat...

Descripción completa

Detalles Bibliográficos
Autores principales: Boilève, Alice, Hilmi, Marc, Delaye, Matthieu, Tijeras-Raballand, Annemilaï, Neuzillet, Cindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198554/
https://www.ncbi.nlm.nih.gov/pubmed/34070929
http://dx.doi.org/10.3390/cancers13112708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198554/
https://www.ncbi.nlm.nih.gov/pubmed/34070929
http://dx.doi.org/10.3390/cancers13112708

Ejemplares similares